Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments

Highlights • lncRNAs are differentially expressed in patients with skin cutaneous melanoma. • We constructed a four-lncRNA signature with the ability of predicting prognosis. • Prognostic signature could potentially improve the prognosis quality of patients.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of dermatological science 2017-03, Vol.85 (3), p.226-234
Hauptverfasser:	Chen, Xijia, Guo, Wenna, Xu, Xin-jian, Su, Fangchu, Wang, Yi, Zhang, Yingzheng, Wang, Qiang, Zhu, Liucun
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant therapy Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Biomarkers, Tumor - analysis Biomarkers, Tumor - metabolism Chemotherapy, Adjuvant Datasets as Topic Dermatology Female Humans Interferons - therapeutic use Kaplan-Meier Estimate lncRNAs Male Melanoma Melanoma - diagnosis Melanoma - mortality Melanoma - pathology Melanoma - therapy Melanoma, Cutaneous Malignant Middle Aged Predictive Value of Tests Prognosis Quality of Life Risk Assessment Risk-stratification RNA, Long Noncoding - analysis RNA, Long Noncoding - metabolism ROC Curve Sentinel Lymph Node Biopsy Skin Neoplasms - diagnosis Skin Neoplasms - mortality Skin Neoplasms - pathology Skin Neoplasms - therapy Transcriptome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • lncRNAs are differentially expressed in patients with skin cutaneous melanoma. • We constructed a four-lncRNA signature with the ability of predicting prognosis. • Prognostic signature could potentially improve the prognosis quality of patients.
ISSN:	0923-1811 1873-569X
DOI:	10.1016/j.jdermsci.2016.12.006